Iqvia announces OCE tech deal with Adhera
Adhera Therapeutics is a specialty pharmaceutical company currently focused on commercializing Prestalia (perindopril arginine and amlodipine besylate), which is US Food and Drug Administration (FDA) approved for the treatment of hypertension to lower blood pressure.
Iqvia last week announced that Adhera has selected the OCE platform to build its commercial infrastructure and bring its specialty drugs to patients.
Last month on the company’s third-quarter earnings call Iqvia CEO Ari Bousbib said the market for its OCE platform represents a “great” opportunity – and the company continues to invest in its technology platform while securing new customers.
In October, Iqvia announced that the pharmaceuticals division of Roche would deploy its commercial technology suite across more than 100 markets as part of the multi-year agreement.
The technologies suite includes the OCE Sales/Marketing, Master Data Management (MDM), ePromo, and Organization Manager applications.
The applications are being rolled out to approximately 14,000 users across more than 100 countries.
Earlier this year the company also won deals with Pierre Fabre, Recordati, and PruGen, among other clients in the US and Canada to deploy its commercial operations SaaS software, OCE.